[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-474744-105":59,"doc-detail-474744-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","staar-surgical-reports-third-quarter-2025-results","STAAR Surgical Reports Third Quarter 2025 Results","","STAAR Surgical reported third-quarter 2025 results for the quarter ended September 26, 2025, highlighting $94.7 million in net sales, a 6.9% year-over-year increase. Gross margin rose to 82.2% from 77.3% a year earlier, driven mainly by the timing of cost-of-sales recognition tied to the December 2024 China ICL shipment. Net income totaled $8.9 million, or $0.18 per diluted share, while adjusted EBITDA increased to $34.6 million. Operating income improved to $18.5 million as operating expenses declined year over year.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/staar-surgical-reports-third-quarter-2025-results/474744/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/staar-surgical-reports-third-quarter-2025-results/474744.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-05","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What were STAAR Surgical’s third-quarter 2025 net sales and how did they change year over year?","Question",{"text":112,"@type":113},"Third-quarter 2025 net sales were $94.7 million, up 6.9% year over year. The report attributes the increase largely to the December 2024 China ICL shipment plus 7.7% growth outside China.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why did gross margin increase in the third quarter of 2025?",{"text":117,"@type":113},"Gross margin rose to 82.2% versus 77.3% a year ago, primarily due to the timing of recognizing cost of sales associated with the December China Shipment. Decreased period costs from first-quarter 2025 cost reductions also contributed.",{"name":119,"@type":110,"acceptedAnswer":120},"How did net income and adjusted EBITDA compare with the prior year quarter?",{"text":121,"@type":113},"Net income was $8.9 million, or $0.18 per diluted share, down from $10.0 million, or $0.20 per diluted share a year earlier. Adjusted EBITDA increased to $34.6 million, or $0.68 per share, from $16.2 million, or $0.33 per share.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},474744,1791024057,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","STAAR Surgical Reports Third Quarter 2025 Results  \nLAKE FOREST, CA, November 5, 2025---STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025.  \nThird Quarter 2025 Financial Overview  \n• Net sales of $94.7 million up 6.9% Y/Y  \n• Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the “December China Shipment”)  \n• Net sales excluding China of $38.9 million up 7.7% Y/Y  \n• Gross margin at 82.2% vs. 77.3% year ago due to the timing of the recognition of the cost of sales associated with the December China Shipment and decreased period costs resulting from cost reductions implemented in the first quarter of 2025  \n• Net income of $8.9 million or $0.18 per share, down from net income of $10.0 million or $0.20 per share year ago  \n• Adjusted EBITDA1 of $34.6 million or $0.68 per share, up from Adjusted EBITDA of $16.2 million or $0.33 per share year ago  \nThird Quarter 2025 Results  \nNet sales were $94.7 million for the third quarter of 2025 compared to $88.6 million in the prior year quarter and $44.3 million in the second quarter of 2025. Net sales for the three months ended September 26, 2025, included $25.9 million related to the previously disclosed December China Shipment, which was paid in full during the third quarter of 2025. The year over year increase in net sales was primarily driven by the December China Shipment combined with 7.7% growth in net sales outside China, partially offset by lower new orders from distributors in China during the third quarter of 2025, due in part to leaner inventory management during the quarter. Excluding China, net sales were $38.9 million, an increase of 7.7% as compared to $36.1 million in the prior year quarter.  \nAs previously disclosed, the Company shipped $27.5 million of ICLs in December 2024 to one of its distributors in China for which the distributor requested extended payment terms through September 2025. Given the extended payment terms, net sales for the shipment were not recognized by the Company until payments were received. The Company recognized $1.6 million related to this shipment in the second quarter of 2025 and the remaining $25.9 million in the third quarter of 2025, in each case upon receipt of corresponding payment. While the remaining $25.9 million related to the shipment was recognized in full during the third quarter of 2025, the associated ICL procedures took place throughout 2025. Sales for the nine months ended September 26,2025 were lower than  \nthe prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million (inclusive of the $27.5 million December China Shipment) instead of purchasing new product from the Company.  \nGross profit margin for the third quarter of 2025 was 82.2% of total net sales compared to the prior year quarter of 77.3% of total net sales and 74.0% of total net sales in the second quarter of 2025. The increase in gross profit margin versus the prior year quarter was due primarily to timing of the recognition of the cost of sales associated with the December China Shipment. The cost of sales for the December China Shipment was recognized in December 2024 when product was shipped, and net sales of $25.9 million was recognized upon payment in September 2025 at 100% gross margin. The increase in gross margin was also due in part to decreased period costs, as a result of cost reductions implemented in the first quarter of 2025.  \nTotal operating expenses for the third quarter of 2025 were $59.4 million, compared to $62.8 million in the prior year quarter. Operating expenses for the quarter included costs related to the Company’s merger with Alcon of ","cbCaieGgLHLc5ttP","https://ap.wps.com/l/cbCaieGgLHLc5ttP","pdf",373599,12,"English","# Third Quarter 2025 Financial Overview\n## Net Sales and Geographic Performance\n## Gross Margin Drivers\n## Operating Expenses and Operating Income\n## Net Income and Tax Effects","[{\"question\":\"What were STAAR Surgical’s third-quarter 2025 net sales and how did they change year over year?\",\"answer\":\"Third-quarter 2025 net sales were $94.7 million, up 6.9% year over year. The report attributes the increase largely to the December 2024 China ICL shipment plus 7.7% growth outside China.\"},{\"question\":\"Why did gross margin increase in the third quarter of 2025?\",\"answer\":\"Gross margin rose to 82.2% versus 77.3% a year ago, primarily due to the timing of recognizing cost of sales associated with the December China Shipment. Decreased period costs from first-quarter 2025 cost reductions also contributed.\"},{\"question\":\"How did net income and adjusted EBITDA compare with the prior year quarter?\",\"answer\":\"Net income was $8.9 million, or $0.18 per diluted share, down from $10.0 million, or $0.20 per diluted share a year earlier. Adjusted EBITDA increased to $34.6 million, or $0.68 per share, from $16.2 million, or $0.33 per share.\"}]","STAAR Surgical Reports Third Quarter 2025 Results | PDF",1790784730]